3.79 -0.07 (-1.81%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 5.1 | 1-year : | 5.96 |
Resists | First : | 4.36 | Second : | 5.1 |
Pivot price | 3.97 | |||
Supports | First : | 3.38 | Second : | 2.77 |
MAs | MA(5) : | 3.87 | MA(20) : | 3.8 |
MA(100) : | 2.72 | MA(250) : | 2.5 | |
MACD | MACD : | 0.1 | Signal : | 0.2 |
%K %D | K(14,3) : | 52.3 | D(3) : | 59.2 |
RSI | RSI(14): 53 | |||
52-week | High : | 4.36 | Low : | 1.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ENLV ] has closed above bottom band by 27.7%. Bollinger Bands are 26% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.97 - 4 | 4 - 4.02 |
Low: | 3.67 - 3.7 | 3.7 - 3.72 |
Close: | 3.75 - 3.8 | 3.8 - 3.83 |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Mon, 25 Mar 2024
Is Enlivex Therapeutics Ltd (ENLV) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Fri, 22 Mar 2024
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on ... - Yahoo Finance
Sat, 16 Mar 2024
Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expands By 51.2% - MarketBeat
Tue, 12 Mar 2024
Is Enlivex Therapeutics Ltd (ENLV) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Thu, 07 Mar 2024
Enlivex Therapeutics Ltd (ENLV) has gained 1.19% Thursday In Premarket Trading - InvestorsObserver
Tue, 05 Mar 2024
Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5% - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 19 (M) |
Shares Float | 15 (M) |
Held by Insiders | 11.8 (%) |
Held by Institutions | 8.9 (%) |
Shares Short | 227 (K) |
Shares Short P.Month | 161 (K) |
EPS | -1.48 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.08 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -28.2 % |
Return on Equity (ttm) | -53.3 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.41 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -23 (M) |
Levered Free Cash Flow | -16 (M) |
PE Ratio | -2.58 |
PEG Ratio | 0 |
Price to Book value | 1.81 |
Price to Sales | 0 |
Price to Cash Flow | -3.06 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |